The Netherlands Antibiotic Development Platform (NADP) launched a novel funding opportunity during the NADP Voucher Event on 22 May 2018. The NADP Vouchers will support researchers and small- or medium-sized enterprises to bring their novel antibiotics and alternatives a step closer to the clinic.
Kees de Joncheere, chairman NADP Executive Board, opened the event with an update of the NADP activities of the past several months. Importantly, he presented the NADP Research and Development Agenda. He was followed by Bernard van Vliet, CEO of INTEGREX Research and Program Manager, Pharma Portal Groningen, who presented on ‘Towards focused and smart antibiotic lead development’. Finally, Liana Steeghs, NADP Executive Board and Managing Director of Immuno Valley, elaborated on the design of the NADP Voucher system and its main conditions.
The plenary presentations were followed by 5-minute pitches of a number of organisations about their services and the support they can provide to capitalise on the NADP Vouchers:
After the pitches the participants could speak with the companies about their expertise.
The NADP Voucher financing instrument includes three vouchers:
Intellectual Property Vouchers
For independent advice on legal support. Vouchers can be used for freedom-to-operate analyses, filing of patent application and other relevant legal support activities. The compensation for the advice and assistance project can be maximally 5,000 euro, corresponding up to 75% of the total project costs.
Value Proposition Vouchers
For independent advice on valorisation options for a new lead. Vouchers can be used for market analyses, drawing up a business plan and/or product development plan, including the development of a target product profile (TPP).The compensation for the advice and assistance project can be maximally 15,000 euro, corresponding up to 75% of the total project costs.
Lead Development Vouchers
For an independent advice, guidance, and execution of a project for the identification, selection and/or validation of a lead compound. Vouchers can be used for lead formulation, selection and optimisation, ADME / DMPK, and toxicology studies. The compensation for the advice and assistance project can be maximally 50,000 euro, corresponding up to 75% of the total project costs.
Availability and budget allocation
The NADP has reserved a budget of approx. 450,000 euro for the period 2018-2020 for this Voucher financing instrument, divided among the Intellectual Property Vouchers, Value Proposition Vouchers and Lead Development Vouchers. The NADP will evaluate the efficacy of the Voucher financing instrument on an annual basis and will amend it as necessary to continue to meet the needs of the applicants.
For whom are the Vouchers intended?
Dutch knowledge institutions and small- or medium-sized enterprises that have a lead for the development of a new antibiotic or alternative therapeutic can submit an application.
What are the conditions?
The Vouchers may only be used for advice and/or supervision and execution of projects pertaining to leads for the development of new antibiotics and alternative therapeutics that comply with the NADP Research and Development Agenda.
Applications can be submitted throughout the year, on a first come, first served basis.
The first of September is the first collection date for all voucher types. Please check the NADP website for further collection dates.
Information on the voucher instrument, including the application forms, is available at the NADP website at https://nadp.nl/nadp-vouchers/
If you have any further technical and practical questions regarding the NADP Voucher financing instrument, please contact Schelto Korf, NADP Alliance Manager via [email protected].
The Netherlands Centre for One Health (NCOH) was allocated a budget of two million euro Public-Private Partnership (PPP) Allowance to organise and realise their first PPP call. This call involves strategic partnerships under the Knowledge and Innovation Agenda of Top Sector Life Sciences & Health (LSH): One Health call.
The number of bacteria that are resistant to antibiotics is increasing globally. In the Netherlands this number remains fairly stable and is lower than in many other countries. Nevertheless, there is still cause for concern and caution. This is evident from the annual report NethMap/MARAN 2019 in which various organisations jointly present data on antibiotic...
A malaria vaccine, based on genetically-manipulated malaria parasites. That is the goal of Meta Roestenberg (LUMC) and Robert Sauerwein (Radboudumc). More than ten years of collaboration is nearing completion. But the vaccine could be even better…
The second edition of the NCOH Magazine has been published at the Annual Scientific Meeting at Radboudumc 17 may. Here is your chance to look at the digital version.